Building the foundations of successful reimbursement & market access
Disruptive Health Tech &
Personalised Medicine
Innovative biotech
Microbiome products
Digital Medicines & Healthcare AI
Start shaping product value early
Value Creation
Value is being created by making appropriate scientific and commercial choices right from the start of the development programme. Know the care environment, healthcare system and competitor situation to shape relevant product profiles.
Generate evidence that supports reimbursement and patient access
Value to Price
In the era of value-based pricing, Health Technology Assessment and growing healthcare budget pressure, your key to optimal price and broad access lies in value demonstration through appropriate evidence.
Share your vision, value proposition and access strategy
Talking Value
Fact : people are not good at communicating scientific concepts, data or complex ideas.
Prepare to share your vision, commercial and access plans for partners, investor & payer confidence.
Shaping asset value from the start: How to integrate the payer and investor point of view into product development
What exactly is the illusive concept of ‘value’? How and why do you leverage product value to achieve optimal pricing, speedy reimbursement and patient access?
Henrike Granzow explains how an actionable plan to understand, strategically define and optimise value-driving product characteristics and benefits in line with defined long-term development goals can help mitigate commercialisation, fundraising and partnering risks.
Precision medicine and integrated care environments: Dynamics in market access and reimbursement.
The health technology space has never been that exciting… and challenging at the same time.
In this white paper, we look at the key developments to keep an eye on in order to better understand your commercial outlook and prepare for market access in precision and patient-centred care. See how abstract dynamics can translate into concrete access impact and how to prepare for pricing, reimbursement and partnering.
What is the EU HTA Regulation? The Joint Clinical Assessment?
How to prepare for the implementation in 2025 and beyond?
How to approach reimbursement and access of Digital Medical Devices?
Reimbursement of digital medical devices (DMD) in Europe remains challenging with few dedicated access pathways and tailored reimbursement schemes. Depending on the type of DMD, some markets may be be more interesting than others. While access strategy needs to be tailored to each device, some general questions for the DMD field should be considered for each evidence generation plan and go-to-market plan.
We build on our longstanding experience in Health Economics, strategic pricing & reimbursement, investor due diligence & portfolio advisory to provide a holistic picture of commercial preparedness
How Apersy
support you
Market access & reimbursement projects
Bespoke training workshops
On-demand support, expert opinion, sense checks
Market Access function support
Get in touch
To hear more about Apersy’s expertise and working approach, for queries, projects and collaborations.
